Slide 1: Third quarter
Third quarter CEO Christer Wahlquist CFO Per-Ola Holmström October 25, 2024 1
Slide 2: Q3 summary – Nolato Group
Q3 summary – Nolato Group A global solutions provider established on three continents ● Sales increased to SEK 2,401 million (2,340) - An increase of 5% adjusted for currency SEKm - Growth for both business areas 12000 ● Operating profit (EBITA) rose by 22% to SEK 235 11000 million (193, excl. non-r
Slide 3: One Group – two business areas
One Group – two business areas Nolato Medical Solutions Engineered Solutions Our offering as a strategic partner for selected Development and manufacture of complex Design, development, industrialization and global customers comprises development and product systems and components for medical manufa
Slide 4: Medical Solutions – sustainable growth and global expansion
Medical Solutions – sustainable growth and global expansion SEKm 5500 5000 4500 4000 3500 3000 1,355 145 2500 2000 SALES EBITA-RESULT SEKm, Q3 SEKm, Q3 1500 1000 56 10.7 500 SHARE OF THE GROUP EBITA-MARGIN 0 05 06 07 08 09 10 11 12 13 14 15 16 17 18 19 20 21 22 23 R12M %, Q3 %, Q3 4 4
Slide 5: Medical Solutions – focused product areas
Medical Solutions – focused product areas Pharma Diagnostics Medical Devices Drug Delivery In-vitro-diagnostics (IVD) Endoscopy & General Surgery Cardiology Continence care Pharma Packaging Other 5
Slide 6: Medical Solutions – Q3
Medical Solutions – Q3 Q3 Acc. 9 months ● 3% increase in sales - An increase of 5% adjusted for currency SEKm 2024 2023 2024 2023 - IVD grew compared with a weak quarter last year - Healthy volumes for Drug Delivery Sales 1,355 1,320 4,075 4,008 - Lower volumes in the Other category (customer produc
Slide 7: Engineered Solutions – advanced technology and high-productivity manufacturing
Engineered Solutions – advanced technology and high-productivity manufacturing SEKm 8000 7500 7000 6500 6000 5500 5000 4500 4000 1,046 103 3500 3000 2500 SALES EBITA-RESULT SEKm, Q3 SEKm, Q3 2000 1500 44 9.8 1000 500 SHARE OF THE GROUP EBITA-MARGIN 0 05 06 07 08 09 10 11 12 13 14 15 16 17 18 19 20 2
Slide 8: Engineered Solutions – focused product areas
Engineered Solutions – focused product areas Materials Consumer electronics Automotive Other Hygiene 8
Slide 9: Engineered Solutions – Q3
Engineered Solutions – Q3 ● 3% increase in sales Q3 Acc. 9 months - An increase of 4% adjusted for currency SEKm 2024 2023 2024 2023 - Significant temporary rise within Hygiene in the quarter - Automotive showed decline in volumes, and lower end-customer demand Sales 1,046 1,020 3,210 3,287 will lik
Slide 10: Group financial highlights
Group financial highlights Full Q3 Acc. 9 months year SEKm 2024 2023 2024 2023 R12M 2023 Net sales 2,401 2,340 7,282 7,294 9,534 9,546 Operating profit (EBITA)* 235 133 718 524 895 701 Operating profit (EBITA), excl. non-recurring item in 2023 235 193 718 584 895 761 EBITA margin (%), excl. non-recu
Slide 11: Current situation
Current situation Medical Solutions Engineered Solutions • Maintained growth strategy – but temporarily sluggish • VHP effects phased out from Q3 2024 market activity • Advanced market positions • Focus on margin – cost adjustments, pricing strategy and • Established position in new product areas ef
Slide 12: Forward-looking statements
This presentation may contain forward-looking statements. When used in this presentation, words such as “anticipate”, “believe”, “estimate”, “expect”, “plan” and “project” are intended to identify forward-looking statements. Such statements could encompass risks and uncertainties pertaining to produ